Arthur Allen - Kaiser Health News

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.

The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities.

As the country faces a rise in infections driven by the BA.5 subvariant, about 70% of people 50 and older who got a first booster shot haven't received the recommended second one, according to the CDC.

The drugmaker has the best-selling vaccine to prevent COVID and the most effective drug to treat it. Its success and might have overshadowed the government’s COVID-fighting strategy.

After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?

The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for COVID. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.

A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.

An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.

As scientists argue whether a previous bout of COVID-19 voffers the same amount of protection as vaccinations, people turn to the courts to decide.